{"id":876260,"date":"2025-08-15T09:13:48","date_gmt":"2025-08-15T13:13:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-reports-fiscal-2025-fourth-quarter-and-full-year-results-highlighting-progress-on-planned-u-s-market-expansion-revenue-growth-and-increased-operational-efficiencies\/"},"modified":"2025-08-15T09:13:48","modified_gmt":"2025-08-15T13:13:48","slug":"intelligent-bio-solutions-reports-fiscal-2025-fourth-quarter-and-full-year-results-highlighting-progress-on-planned-u-s-market-expansion-revenue-growth-and-increased-operational-efficiencies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intelligent-bio-solutions-reports-fiscal-2025-fourth-quarter-and-full-year-results-highlighting-progress-on-planned-u-s-market-expansion-revenue-growth-and-increased-operational-efficiencies\/","title":{"rendered":"Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies"},"content":{"rendered":"
\n

\n Company advanced efforts to secure U.S. FDA 510(k) clearance<\/em>
\n to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings<\/em>\n <\/p>\n

\n Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges<\/em>\n <\/p>\n

NEW\u00a0YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.<\/p>\n

Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cartridge sales, operational streamlining, and regulatory advancements that support future expansion in the U.S. market, beyond current Forensic Use Only settings. The Company continues to expand its commercial presence internationally, with an active customer base exceeding 450 accounts across 24 countries, and 18 distribution partners.<\/p>\n

\n \u201cFiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth,\u201d said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. <\/em>
\n \u201cWe delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we\u2019re focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S<\/em>. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world\u2019s largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.\u201d<\/em><\/p>\n

\n Progress Toward FDA Clearance and U.S. Market Expansion<\/strong>\n <\/p>\n

INBS remains focused on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., enabling broader use beyond current Forensic Use Only settings. In fiscal 2025, the Company advanced its regulatory strategy through increased engagement with regulatory consultants, refined clinical study design, and the generation of new scientific and clinical data to support its submission.<\/p>\n